Mayo Clinic launches 2 new companies to use patient data and AI to advance early disease detection
Related Articles
Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failureOctober 02, 2023
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
BioSpace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer Inc. for Anumana to develop an artificial intelligence electrocardiogram…December 15, 2022
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the…June 21, 2023
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 15, 2022